Compare ASIC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | ODTX |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2025 | 2025 |
| Metric | ASIC | ODTX |
|---|---|---|
| Price | $24.36 | $19.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $28.40 | ★ $34.67 |
| AVG Volume (30 Days) | 73.7K | ★ 287.4K |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $424,339,000.00 | N/A |
| Revenue This Year | $24.89 | N/A |
| Revenue Next Year | $22.34 | N/A |
| P/E Ratio | $16.69 | ★ N/A |
| Revenue Growth | ★ 23.41 | N/A |
| 52 Week Low | $16.73 | $15.10 |
| 52 Week High | $29.00 | $29.05 |
| Indicator | ASIC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 48.61 |
| Support Level | $23.36 | $18.87 |
| Resistance Level | $25.62 | $19.60 |
| Average True Range (ATR) | 0.84 | 1.78 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 62.35 | 33.45 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.